Targeted neoadjuvant therapy in the HER-2-positive breast cancer patients: a systematic review and meta-analysis.

To evaluate efficacy and safety of lapatinib or trastuzumab alone or both plus chemotherapy for the treatment of breast cancer patients with positive HER-2 expression.